Celsion Corporation (NASDAQ:CLSN)’s share price shot up 7% during trading on Monday . The company traded as high as $2.21 and last traded at $2.14. 3,002,492 shares were traded during trading, an increase of 110% from the average session volume of 1,428,975 shares. The stock had previously closed at $2.00.

A number of brokerages recently commented on CLSN. Maxim Group restated a “hold” rating on shares of Celsion Corporation in a report on Tuesday, August 15th. Oppenheimer Holdings, Inc. started coverage on Celsion Corporation in a report on Tuesday. They issued an “outperform” rating and a $9.00 price objective for the company. ValuEngine upgraded Celsion Corporation from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Zacks Investment Research downgraded Celsion Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, October 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. Celsion Corporation has a consensus rating of “Buy” and an average target price of $11.90.

A hedge fund recently bought a new stake in Celsion Corporation stock. Sabby Management LLC acquired a new stake in shares of Celsion Corporation (NASDAQ:CLSN) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 108,843 shares of the biotechnology company’s stock, valued at approximately $223,000. Sabby Management LLC owned about 1.30% of Celsion Corporation at the end of the most recent reporting period. Hedge funds and other institutional investors own 6.41% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Celsion Corporation (CLSN) Shares Up 7%” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/celsion-corporation-clsn-shares-up-7/1719919.html.

Celsion Corporation Company Profile

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.